Navigation Links
When acute hepatitis develops into chronic hepatitis
Date:2/17/2009

To achieve this, Carlos A. Guzmn, Head of the "Vaccinology and Applied Microbiology" working group and Robert Geffers, Head of the "Gene Expression Analysis" platform, examined the incidence and species of special defence cells, T helper cells, along with their role in the development of the disease in conjunction with their Indian colleagues. With the aid of genetic analysis, they showed how the genes in these immune cells are regulated differently according to the development of the disease. These new results can help doctors to discover whether an infection is curable or whether by settling in the liver, it will develop into a chronic case. These results are now published in the scientific journal, Hepatology.

Approximately 300 to 420 million people (5 to 7% of the world's population) have a chronic hepatitis B infection. India is one of the countries, in which hepatitis B is very common. A differentiation is made with the development of the disease between acute and chronic hepatitis B. The most common symptom of an acute infection is jaundice. In 5% of the infections, the disease becomes chronic, that is to say, the viruses remain in the liver. If left untreated, chronic hepatitis B can lead to a change in consciousness, cirrhosis and cancer of the liver. Until today scientists have not fully understood the role that the immune system plays in characterising an acute or chronic hepatitis B infection.

A decisive factor in achieving an appropriate immune reaction is the quick mobilisation of immune cells. These specifically attack the infected liver cells without destroying any unnecessary liver tissue in the process. Subspecies of the T helper cells play a decisive role in achieving this necessary balance between immunological defence and tolerance: effector T cells and regulatory T cells (Treg). Whilst the effector T cells fight a virus infection and kill off the infected host cells, the Treg cells shut down an immune reaction and
'/>"/>

Contact: Dr. Bastian Dornbach
bad@helmholtz-hzi.de
49-053-161-811-407
Helmholtz Association of German Research Centres
Source:Eurekalert

Page: 1 2

Related biology news :

1. Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage
2. Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
3. Scientists suspect omega-3 fatty acids could slow acute wound healing
4. Predicting acute GVHD by gene expression could improve liver stem cell transplant outcomes
5. Discovery could lead to a new animal model for hepatitis C
6. Leeds research points to new therapy for hepatitis C treatment
7. Nano vaccine for hepatitis B shows promise for third world
8. Hepatitis C virus may need enzymes help to cause liver disease
9. BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients
10. New hope for hepatitis C sufferers
11. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 26, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... a new corporate website ( http://www.nxt-id.com/ ) as part ... Wocket™ smart wallet. The Company launched its new consumer ... Gino Pereira , CEO of NXT-ID said, "Our ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... in cells that may help to kill tumors with heat. ... by a combination of heat and an anti-cancer drug that ... ability of heat to switch off essential survival mechanisms in ... underlying principles are still unclear. In a recent publication ...
... with large, lace-like wings that live in a wide variety ... but the larvae are ferocious predators of other insects, frequently ... after killing them using their enormous, sucking tube-like jaws. ... in the genus Semachrysa is described from the ...
... that the extremely hot, dry and windy conditions on Black ... rolls, -similar to streamers of wind flowing through the air ... the first of its kind to produce such detailed, high-resolution ... for future fire management and warning systems. The work ...
Cached Biology News:Unusual weather events identified during the Black Saturday bushfires 2
(Date:3/3/2015)... , March 3, 2015  Regenicin, Inc. (OTC Bulletin ... in the development of and commercialization of regenerative cell ... organs, announced today that it has received the final ... Bioscience Holdings, Inc. (OTC Bulletin Board: AMBS ... Amarantus made the final payments due to Regenicin in ...
(Date:3/3/2015)...  Thingee Corporation, a software development company for the ... "Technology Adoption: Making Reps, Lives Easier" during the 2015 ... ,  in Deerfield Beach, Florida , ... looking to learn how technology can help them do ... the audience for the Thingee presentation. ...
(Date:3/3/2015)... Genedata, a leading provider of ... science research, today announced that Pfizer Inc. has ... use at Pfizer biopharma research and development sites ... Pfizer’s global deployment and roll out project at ... Innovation (CTI), and Pharmaceutical Sciences groups. , ...
(Date:3/3/2015)... FRANCISCO , March 3, 2015  Johnson & ... @ South San Francisco (JLABS @SSF), ... Boulevard, South San Francisco, Calif. ... accommodate up to 50 startups from across the healthcare ... health.  The first resident startups have ...
Breaking Biology Technology:Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Thingee to present at 11th Annual Synergistix Users Conference 2Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5
... Stallergenes,S.A. officially inaugurates its new pharmaceutical production ... comply with the most stringent EMEA (European Medicines,Agency) ... this unit will,produce desensitisation treatments for all markets, ... worth more than 20 million euros will incorporate ...
... Sept. 10 Signalife, Inc. (Amex:,SGN) announced that the company,s ... stock to be effected in the form of a,reverse stock ... on September,19, 2008, which will be the record date and ... time of such reverse stock split, all,outstanding shares of Signalife ...
... - Abstracts 185 and 1112, Sanofi-aventis, ... from,two randomized clinical studies presented at the European ... Meeting demonstrating that the,"basal plus" insulin strategy with ... insulin) and APIDRA(R) once daily,(prandial insulin) (insulin glulisine ...
Cached Biology Technology:Stallergenes Inaugurates the Biggest Pharmaceutical Allergen Production Unit in the World 2Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 2Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 3Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 4Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 5Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 6Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 2Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 3Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 4
... Processing Standard Tray (3 per pack), ... staining and blot processing.Automated staining of ... proteins and nucleic acid analysis.Prepares blots ... chromogenic detection.Programmable control of protocol, solution, ...
DITHIOTHREITOL, 150UMOL, 1 EA. Dithiothreitol (DTT), 0.1 M Solution:, *0.1 M solution of DTT in high purity dH2O., *0.2 m filtered., *Storage: -20C. Category: SEQUENASE....
GOAT ANTI HUMAN PARAINFLUENZA VIRUS 2+3...
75 x 25 mm; sterile, recommended for immunohistochemistry of cell lines growing in suspension, Poly-D-Lysine coated, glass slides with polystyrene vessel, lid and safety removal tool...
Biology Products: